000			02041 a2200517 4500
005			20250514201754.0
264		0	_c20041209
008			200412s 0 0 eng d
022			_a0006-291X
024	7		_a10.1016/j.bbrc.2004.08.169 _2doi
040			_aNLM _beng _cNLM
100	1		_aSorel, N
245	0	0	_aEvidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. _h[electronic resource]
260			_bBiochemical and biophysical research communications _cOct 2004
300			_a728-30 p. _bdigital
500			_aPublication Type: Comparative Study; Evaluation Study; Journal Article
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBenzamides
650	0	4	_aCell Differentiation _xdrug effects
650	0	4	_aCells, Cultured
650	0	4	_aDrug Resistance _xgenetics
650	0	4	_aEnzyme Inhibitors _xadministration & dosage
650	0	4	_aFusion Proteins, bcr-abl _xgenetics
650	0	4	_aGene Expression Regulation, Neoplastic _xdrug effects
650	0	4	_aGenetic Predisposition to Disease _xgenetics
650	0	4	_aGenetic Testing _xmethods
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy
650	0	4	_aMutation
650	0	4	_aPhosphotransferases _xantagonists & inhibitors
650	0	4	_aPiperazines _xadministration & dosage
650	0	4	_aProtein Structure, Tertiary
650	0	4	_aPyrimidines _xadministration & dosage
650	0	4	_aSequence Analysis, Protein
650	0	4	_aStem Cells _xdrug effects
650	0	4	_aStructure-Activity Relationship
650	0	4	_aTumor Cells, Cultured
700	1		_aBonnet, M L
700	1		_aGuillier, M
700	1		_aGuilhot, F
700	1		_aBrizard, A
700	1		_aTurhan, A G
773	0		_tBiochemical and biophysical research communications _gvol. 323 _gno. 3 _gp. 728-30
856	4	0	_uhttps://doi.org/10.1016/j.bbrc.2004.08.169 _zAvailable from publisher's website
999			_c15074293 _d15074293